N-(2,4-Dimethylphenyl)-N-methylimidoformamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2,4-Dimethylphenyl)-N-methylimidoformamide
• 英文别名: N-(2,4-dimethylphenyl)-N-methylmethanimidamide
• 化学式: C₁₀H₁₄N₂
• 分子量: 162.23
• InChiKey: UBLNTZNUSGCINZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  27.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Substituted benzophenone hydrazones, pesticidal compositions containing them and method of combating pests
  申请人：FBC LIMITED

  公开号：EP0026040A1

  公开（公告）日：1981-04-01

  Substituted benzophenone hydrazones offormula I in which R, Q, R2 and R' have the meaning given in the description. The hydrazones have pesticidal activity, especially against insects and acarids, and pesticidal compositions and methods are described. Methods of making the hydrazones are also described.

  式 I 的取代二苯甲酮酰肼 其中 R、Q、R2 和 R' 具有说明中给出的含义。 这些肼具有杀虫活性，特别是对昆虫和害虫的杀虫活性，并描述了杀虫组合物和杀虫方法。还描述了制造肼酮的方法。
• Methods for treating ocular demodex using isoxazoline parasiticide formulations
  申请人：Tarsus Pharmaceuticals, Inc.

  公开号：US10835517B2

  公开（公告）日：2020-11-17

  Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.

  本文公开了治疗或预防患者眼科和皮肤病的方法，包括眼表疾病，如眼睑炎。这些方法可包括直接向需要治疗的患者的一只或多只眼睛的眼表面局部施用有效量的异噁唑啉杀寄生虫剂、甲脒杀寄生虫剂或其他活性成分，配制成眼科组合物，该眼科组合物进一步包括药学上可接受的载体。还公开了组合物。
• Isoxazoline parasiticide formulations and methods for treating blepharitis
  申请人：Tarsus Pharmaceuticals, Inc.

  公开号：US11197847B2

  公开（公告）日：2021-12-14

  Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.

  本文公开了治疗或预防患者眼科和皮肤病的方法，包括眼表疾病，如眼睑炎。这些方法可包括直接向需要治疗的患者的一只或多只眼睛的眼表面局部施用有效量的异噁唑啉杀寄生虫剂、甲脒杀寄生虫剂或其他活性成分，配制成眼科组合物，该眼科组合物进一步包括药学上可接受的载体。还公开了一些组合物。
• ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITIS
  申请人：Tarsus Pharmaceuticals, Inc.

  公开号：EP3723739A1

  公开（公告）日：2020-10-21
• SYSTEMIC ISOXAZOLINE PARASITICIDES FOR VECTOR-BORNE AND VIRAL DISEASE TREATMENT OR PROPHYLAXIS
  申请人：Tarsus Pharmaceuticals, Inc.

  公开号：EP3946325A1

  公开（公告）日：2022-02-09